Robust, well characterized preclinical models are essential for the advancement of targeted therapies for colorectal cancer. Patient derived xenografts (PDX) models display a true representation of the human genetic and phenotypic heterogeneity seen in patient populations and provide the most accurate approach to predicting an agent’s efficacy prior to entering the clinic. CrownBio has one of the largest collections of colorectal cancer PDX models, including subcutaneous and orthotopic models to more closely recapitulate the tumor microenvironment. This collection is well published and can be referenced in the following publications: More
-A set of defined oncogenic mutation alleles seems better predict the response to cetuximab in CRC patient-derived xenograft disease than KRAS 12/13 mutations.pdf
-Cetuximab response in CRC patient-derived xenograft seems predicted by an expression based Ras pathway signature.pdf
-Molecular pathology of patient tumors, patient derived xenografts and cancer cell lines.pdf
Patient-derived xenografts (PDX) offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials.
CrownBio’s HuPrime® PDX collection well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.